Shanghai Haohai Biological Technology (HKG:6826) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥670.4m (flat on 3Q 2023).
- Net income: CN¥105.6m (down 13% from 3Q 2023).
- Profit margin: 16% (down from 18% in 3Q 2023).
- EPS: CN¥2.19.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Haohai Biological Technology Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Shanghai Haohai Biological Technology's balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.